Credit: Dana-Farber Cancer Institute
Phase 3 clinical trial led by Dana-Farber Cancer Institute tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.
close
-
News keyboard_arrow_right
Latest News Coronavirus News Currently Embargoed News Research News Releases Google Fact Check Research Alert Preprints Marketplace News with Video/Audio
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right